Q-omics provides the consensus-scored PDCD6IPP2 profile across patient tissues and cancer cell-line models. PDCD6IPP2 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PDCD6IPP2 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, PDCD6IPP2 RNA expression shows 15,462 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and THCA as cancer lineages where PDCD6IPP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDCD6IPP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDCD6IPP2 survival associations across molecular data types. PDCD6IPP2 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDCD6IPP2 RNA expression–survival associations across cancer types. High PDCD6IPP2 expression shows unfavorable associations in UVM, LAML, BLCA, LGG and BRCA, but favorable associations in LUAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PDCD6IPP2 RNA expression.
This table summarizes PDCD6IPP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for PDCD6IPP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDCD6IPP2 shows lower tumor expression in THCA, COAD and BRCA and higher tumor expression in KIRP, KIRC and LIHC. The THCA box plot shows higher PDCD6IPP2 RNA expression in normal versus tumor tissue (log2 FC = −1.805, t-test p < 0.001).
This table shows molecular features associated with PDCD6IPP2 in patient tissues and cancer cell lines. In patient samples, PDCD6IPP2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
